Turkish Journal of Gastroenterology
Original Articles

A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate

1.

Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Türkiye

2.

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Turkey, Haseki Training and Research Hospital, İstanbul, Türkiye

3.

Department of Infectious Diseases and Clinical Microbiology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Türkiye

4.

Department of Infectious Diseases and Clinical Microbiology, İzmir City Hospital, İzmir, Türkiye

5.

Department of Infectious Diseases and Clinical Microbiology, Samsun University Faculty of Medicine, Samsun, Türkiye

6.

Department of Infectious Diseases and Clinical Microbiology, İstanbul Lutfi Kırdar Kartal Training and Research Hospital, İstanbul, Türkiye

7.

Department of Infectious Diseases and Clinical Microbiology, Ankara Yıldırım Beyazıt Faculty of Medicine, Ankara, Türkiye

8.

Department of Infectious Diseases and Clinical Microbiology, Adana Health Sciences University Faculty of Medicine, Adana, Türkiye

9.

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Türkiye

10.

Department of Infectious Diseases and Clinical Microbiology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul, Türkiye

11.

Department of Infectious Diseases and Clinical Microbiology, Sakarya University Medical Faculty, Sakarya, Türkiye

12.

Department of Infectious Diseases and Clinical Microbiology, Recep Tayyip Erdoğan University Faculty of Medicine, Rize, Türkiye

13.

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ümraniye Training and Research Hospital, İstanbul, Türkiye

14.

Department of Infectious Diseases and Clinical Microbiology, Bakırçay University, Çiğli Training and Research Hospital, İzmir, Türkiye

15.

Department of Infectious Diseases and Clinical Microbiology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Türkiye

16.

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, İstanbul Training and Research Hospital, İstanbul, Türkiye

17.

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Türkiye

18.

Department of Infectious Diseases and Clinical Microbiology, Bolu Abant Izzet Baysal Faculty of Medicine, Bolu, Türkiye

19.

Department of Infectious Diseases and Clinical Microbiology, Fırat University Faculty of Medicine Elazığ, Türkiye

Turk J Gastroenterol 2025; 1: -
DOI: 10.5152/tjg.2025.24741
Read: 27 Downloads: 16 Published: 23 October 2025

Background/Aims: Selecting the initial antiviral regimen for chronic hepatitis B (CHB) requires balancing patients’ comorbidities and long-term safety. This study examines differences in patient and disease-related factors that guide clinicians to prescribe either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) as the initial treatment.

Materials and Methods: The study included treatment-na.ve CHB patients aged 18 or older who had been diagnosed for at least 1 year since 2010 and initiated on antiviral therapy. The data included variables such as age, gender, body mass index (BMI), comorbidities,liver disease activity, biopsy results, cirrhosis, hepatic steatosis, hepatitis B e-antigen status, hepatitis B virus DNA levels, triglycerides,cholesterol, renal function, and baseline bone mineral density (BMD), which were assessed by dual-energy x-ray absorptiometry (DEXA).

Results: Among 2259 patients (61.6% male), 1270 patients (56.22%) received TDF, while 989 patients (43.78%) received ETV as firstline therapy. The TDF was more commonly prescribed to patients with a lower BMI (median 25.7 vs. 26.2, P = .001) and lower baseline creatinine (0.75 vs. 0.80 for ETV, P < .001). Clinicians preferred ETV among patients with an estimated glomerular filtration rate (eGFR) <60 (n = 36), (P < .001). The BMD was evaluated in 365 patients (16.3%). The DEXA scans were performed for 116 patients (11.8%) in the ETV group and 249 patients (19.8%) in the TDF group (P < .001).

Conclusions: This national multicenter study emphasizes that patient-related factors, including gender, age, baseline renal function, and liver disease severity, significantly influence the choice of first-line antiviral therapy for CHB, often outweighing disease-specific factors.

 

Cite this article as: Yamazhan T, Zerdali E, .nlen Y, et al. A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus tenofovir disoproxil fumarate. Turk J Gastroenterol. Published online October 23, 2025.doi:10.5152/tjg.2025.24741.

Files
EISSN 2148-5607